Table 1 Demographics, co-morbid conditions and antifungal therapy of study groups.
From: Statins in Candidemia: clinical outcomes from a matched cohort study
Variable | Patients on Statins N (% or +/- SD) | Patients Not on Statins N (% or SD) | p-value†|
|---|---|---|---|
Age (years) | 65.9 (+/- 9.4) | 67.7 (+/- 8.7) | 0.52 |
Male | 11 (73%) | 12 (40%) | 0.06 |
Medical ICU | 9 (60%) | 24 (80%) | 1 |
Median Charlson Score (IQR) | 8 (5-8) | 6 (5-7) | 0.15 |
Apache II | 14.9 (+/- 3.8) | 18.2 (+/- 5.0) | 0.03* |
AST | 20 [17,140] | 34 [24,86] | 0.34 |
ALT | 22 [19,135] | 44 [24,113] | 0.17 |
Albumin | 2 (+/- 0.3) | 2 (+/- 0.5) | 0.76 |
Bicarbonate | 23.9 (+/- 5.6) | 22.9 (+/- 5.5) | 0.57 |
Creatinine | 2.8 (+/- 2.3) | 2.7 (+/- 1.7) | 0.80 |
CPK | 129 [39,1502] | 45 [35,163] | 0.45 |
Hematocrit | 29.8 (+/- 4.2) | 29.2 (+/- 4.9) | 0.66 |
PT | 14.2 (+/- 2.4) | 14.0 (+/- 2.9) | 0.79 |
PTT | 31.6 (+/- 8.6) | 39.3 (+/- 16.9) | 0.06 |
WBC | 12.2 (+/- 4.5) | 16.8 (+/- 8.8) | 0.02* |
Platelets | 241 (+/- 127) | 221 (+/- 130) | 0.62 |
Heart disease | 15 (100%) | 16 (53%) | <0.01* |
Heart failure | 7 (47%) | 6 (20%) | 0.08 |
Obstructive lung disease | 4 (27%) | 8 (27%) | 1.0 |
Renal insufficiency | 7 (47%) | 7 (23%) | 0.08 |
Dialysis | 4 (27%) | 9 (30%) | 1.0 |
Stroke | 6 (40%) | 7 (23%) | 0.3 |
Cancer | 2 (13%) | 4 (13%) | 1.0 |
Diabetes | 10 (67%) | 17 (57%) | 0.75 |
HIV/AIDS | 0 | 0 | Â |
Hypertension | 12 (80%) | 20 (67%) | 0.49 |
Peripheral vascular disease | 5 (33%) | 2 (7%) | 0.03* |
Transplantation | 1 (7%) | 1 (3%) | 1.0 |
Median duration of Candidemia (days) | 2 (+/-0.6) | 1 (+/-0.9) | 0.2 |
Survival | 11 (73%) | 11 (37%) | 0.02* |